Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma

Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma

PR Newswire

LONDON, March 14, 2013

LONDON, March 14, 2013 /PRNewswire/ --

The expiration of patents on several blockbuster drugs has been one of the
major trends in the biotechnology sector in the last few years. As major
pharmaceutical companies face increasing generic competition following patent
expirations, they are likely to see a negative impact on their top-line. Big
pharmaceutical companies have been looking to boost their product pipeline to
offset the impact of the patent cliff. Another trend that could emerge as a
result of this development is acquisitions. Big pharma companies may look to
acquire smaller biotechnology companies that are developing potential
blockbuster drugs. Companies such as Sequenom Inc. (NASDAQ: SQNM), Peregrine
Pharmaceuticals (NASDAQ: PPHM), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and
Inovio Pharmaceuticals Inc. (NYSEAMEX: INO) could be among the ideal takeover
targets for major pharmaceutical companies. On Wednesday, biotech stocks ended
on a mixed note even as the Dow Jones posted its ninth successive higher
finish. StockCall has posted free technical research reports on SQNM, PPHM,
ONXX, and INO and these can be accessed by signing up at

Sequenom Inc. shares posted modest gains on Wednesday, closing 0.45% higher at
$4.48. The stock touched an intra-day high of $4.51, and has gained nearly 4%
this week. Despite the recent gains, the biotech company's shares have fallen
nearly 5% this year, even as the broad market has posted significant gains for
the year. The company's shares have been struggling to break through $4.60
resistance level. The stock has just moved above its 50-day moving average,
though, which is a bullish signal. The stock's MACD has also crossed above the
zero-line, which further confirms the positive trend. Download the free
report on SQNM upon registration at 

Peregrine Pharmaceuticals shares saw a sharp decline in Wednesday's session as
investors digested the company's quarterly results. The stock closed 6.33%
lower at $1.48 after touching an intra-day low of $1.43. The company's shares
are down more than 10% for the week. Despite the recent losses, the stock has
outperformed the broad market this year. Year-to-date, Peregrine's shares have
gained over 12% as compared to a jump of 9% for the S&P 500. The MACD chart
for PPHM is giving bearish signal at the moment. The stock is also trading
below its 50-day moving average. PPHM technical report can be accessed for
free by signing up at 

Although Onyx Pharmaceuticals Inc. shares edged lower in trading yesterday,
losses were limited. The stock ended the day 0.61% lower at $87.29 after
falling to an intra-day low of $88.55. Onyx's shares are up nearly 2% for the
week, despite Wednesday's pullback. The stock has had an excellent run so far
this year, gaining more than 15%. The company's shares have seen a series of
highs over the last few trading sessions, which is a bullish signal. The
upbeat trend is confirmed by recent volume activity. The free report on ONXX
can be downloaded by signing up now at 

Shares of Inovio Pharmaceuticals Inc. gained in the previous trading session,
closing 0.43% higher at $0.540 on above average volume of 2.99 million
yesterday. Inovio's shares had fallen sharply last week; however, the stock
has bottomed out at around $0.525. Free report on INO can be accessed by
registering at 

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at


Contact: Contact Person:William T. Knight, Email: , Contact
Number: +1-646-396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.